Survival benefit for early hormone ablation in biochemically recurrent prostate cancer (Q44927709)

7 December 2017

title

Survival benefit for early hormone ablation in biochemically recurrent prostate cancer (English)

1 reference

7 December 2017

Todd C Tenenholz

1

1 reference

7 December 2017

Christian Shields

2

1 reference

7 December 2017

V Ramakrishnan Ramesh

3

1 reference

7 December 2017

Oscar Tercilla

4

1 reference

7 December 2017

Michael P Hagan

5

1 reference

7 December 2017

publication date

1 March 2007

1 reference

7 December 2017

1 reference

7 December 2017

volume

25

1 reference

7 December 2017

issue

2

1 reference

7 December 2017

page(s)

101-109

1 reference

Variables in predicting survival based on treating "PSA-only" relapse

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

Initiation of salvage therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

National Comprehensive Cancer Network guidelines for the management of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

Natural history of progression after PSA elevation following radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

Prostatic-specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

Current evidence for the role of combined androgen suppression and radiation in the treatment of adenocarcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

Androgen ablation in addition to radiation therapy for prostate cancer: is there true benefit?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

Quality of life following definitive therapy for localized prostate cancer: potential impact of multiple therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: a survey of practice patterns of urologists and radiation oncologists in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.03.002

10.1016/J.UROLONC.2006.03.002

7 January 2021

Identifiers

DOI

1 reference

7 December 2017

1 reference